Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Danoprevir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danoprevir SCHEMBL1444652 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL11939425 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL6370805 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL10238838 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL17970113 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL11983895 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL23948382 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL12188232 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL1444650 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB | |
| Danoprevir SCHEMBL7873481 | 1.00 | CYP3A4 (0.39) | CYP3A4ADRB3ADRA2BADRA2CCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2025264805-A2 | SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| WO-2024182434-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2024-09-06 | — | — | WO | claimed |
| US-20240165143-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2024-05-23 | — | — | US | claimed |
| CN-114867351-B | 4' -Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses | 埃默里大学 | 2024-04-23 | — | — | CN | claimed |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | HOTH THERAPEUTICS, INC. | 2023-11-02 | — | — | US | claimed |
| US-20230158088-A1 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, ENHANCING DRUG POTENCY AND TREATING VIRAL INFECTIONS, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | claimed |
| WO-2023069981-A1 | USES OF TAXIFOLIN FOR RESPIRATORY HEALTH | PHYTO TECH CORP. (US) | 2023-04-27 | — | — | WO | claimed |
| US-20230119141-A1 | USES OF TAXIFOLIN FOR RESPIRATORY HEALTH | PHYTO TECH CORP. | 2023-04-20 | — | — | US | claimed |
| EP-4040965-A2 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Emory University (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114867351-A | 4' -halo-containing nucleotide and nucleoside therapeutic compositions and uses related thereto | 埃默里大学 | 2022-08-05 | — | — | CN | claimed |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | MODEL MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| WO-2008046860-A2 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-24 | — | — | WO | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | ARRAY BIOPHARMA, INC. | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | SARS1, ITK, SLC43A1 | CYP3A4 1770/4885ADRB3 1888/4885ADRA2B 3125/4885 |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | CYP3A4 581/4885ADRB3 360/4885ADRA2B 824/4885 |
| US-20260102384-A1 | USE OF PIPENDOXIFENE FOR TREATING INFECTIONS OF DNA VIRUSES | ESR1, VDR, POLL | CYP3A4 157/4885ADRB3 1383/4885ADRA2B 1833/4885 |
| US-20070054842-A1 | Novel macrocyclic inhibitors of hepatitis C virus replication | EIF2AK2, HAVCR2, HCCS | CYP3A4 826/4885ADRB3 4572/4885ADRA2B 4492/4885 |
| US-20230119141-A1 | USES OF TAXIFOLIN FOR RESPIRATORY HEALTH | ACE2, MAVS, ACE | CYP3A4 3248/4885ADRB3 3085/4885ADRA2B 3392/4885 |
| US-20260124192-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF TREATING RNA VIRAL INFECTIONS | SARS1, NSUN2, NSUN3 | CYP3A4 403/4885ADRB3 1682/4885ADRA2B 2929/4885 |
| US-20240165143-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | CYP3A4 1437/4885ADRB3 1934/4885ADRA2B 3112/4885 |
| US-20230346792-A1 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | ACE2, TMPRSS2, VIPR1 | CYP3A4 1773/4885ADRB3 314/4885ADRA2B 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.